论文部分内容阅读
替尼泊苷 (ＶＭ 2 6 )和依托泊苷 (ＶＰ 16 )是小细胞肺癌 (ＳＣＬＣ)的有效的抗肿瘤药物。ＶＰ 16 +顺铂 (ＤＤＰ)已确认为ＳＣＬＣ标准化疗方案 ,而对ＶＭ 2 6 +ＤＤＰ注意不够 ,我们 1995年 1月— 1998年 12月应用两方案治疗非小细胞肺癌 (ＳＣＬＣ)均取得较好效果。材料和
Teniposide (VM 26) and etoposide (VP 16) are effective antitumor drugs for small cell lung cancer (SCLC). VP 16 + cisplatin (DDP) has been identified as a standard chemotherapy regimen for SCLC, while insufficient attention has been paid to VM 26 + DDP. We have achieved comparable outcomes with both regimens for the treatment of non-small cell lung cancer (SCLC) from January 1995 to December 1998. Good effect. Material and